宫氏脑针治疗顽固性癌痛的机制及临床研究

目的:探讨宫氏脑针治疗顽固性癌痛的机制及临床效果。方法:抽取2018年8月至2020年5月期间深圳市罗湖区中医院及中国科学院大学深圳医院(光明)收治的120例顽固性癌痛患者,采取随机数字表法随机将患者分为两组,分别为A组(n=60,宫氏脑针联合吗啡)及B组(n=60,吗啡),比较两组患者的数字评分法(NRS)情况、吗啡日用剂量、血清前列腺素E2(PGE2)、β–内啡肽(β–EP)、内皮素–1(ET–1)及药物不良反应发生率。结果:治疗开始两组患者的NRS评分、吗啡使用日剂量比较,差异无统计学意义(P>0.05);治疗后两组患者的NRS评分、吗啡使用日剂量均有不同程度降幅,且A组降幅大于B组,差异具有统计学意义(P<0.05)。治疗前两组患者的PGE2、β–EP及ET–1比较,差异无统计学意义(P>0.05);治疗后两组患者的PGE2、β–EP及ET–1均得以下降,且A组下降幅度大于B组,差异具有统计学意义(P<0.05)。A组不良反应发生率为10.00%低于B组的31.67%,差异具有统计学意义(P<0.05)。结论:针对顽固性癌痛患者,宫氏脑针治疗可有效缓解疼痛,减少吗啡使用剂量,降低患者血清内PGE2、β–EP、ET–1等疼痛介质水平,患者不良反应发生率得以减少。

Mechanism and Clinical Study of Gongshi Brain Acupuncture in the Treatment of Intractable Cancer Pain

Objective To explore the mechanism and clinical effect of Gongshi brain acupuncture in the treatment of intractable cancer pain.Methods From August 2017 to may 2020,120 patients with intractable cancer pain admitted to the Department of oncology,Luohu District Hospital of traditional Chinese medicine and Guangming New District People’s Hospital of Shenzhen were selected as the research objects.The patients were randomly divided into two groups by random number table method:group A(n=60,Gongshi Nao Zhen+morphine)and B group Pain score,daily dose of morphine,serum PGE2,β-endorphin,ET-1 factor and incidence of adverse drug reactions were compared between the two groups.Result After treatment,the NRS score of the two groups decreased,and the daily dose of morphine decreased,and the score of the observation group decreased more,and the daily dose of morphine was less(P<0.05);the PGE2,β-EP and ET-1 of the two groups were decreased before and after treatment,and the decrease range of group A was more significant(P<0.05);the adverse reaction rate of group A was 10.00%,which was significantly lower than that of group B(31.67%)(P<0.05).Conclusion For patients with intractable cancer pain,Gongshi brain acupuncture can effectively relieve pain,reduce the dosage of morphine,reduce the level of pain mediators such as PGE2,β-endorphin,ET-1 in serum,and reduce the incidence of adverse reactions.